Payment overview · 2025
General Payments
$122.75
7 reported records · 4 companies
Healthcare provider profile · identity verified
Bruce D Scully, MD
Allopathic & Osteopathic Physicians|Family Medicine · BLUE SPRINGS, MO · NPI 1366437972
Verified facts
What the public records show
CMS Open Payments records show Bruce D Scully, MD received $122.75 in general payments during 2025 across 7 reported records.
Novo Nordisk Inc accounted for 41.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $50.63 | 41.2% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $40.71 | 33.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.99 | 13.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.42 | 12.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $122.75 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $35.80 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $24.62 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $24.62 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.90 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $16.09 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $16.09 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.99 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.99 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.42 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $15.42 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.42 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.83 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 76 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 93 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 117 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
76 | 26 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
48 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
93 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
53 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
117 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
104 | 33 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 727 | 167 |
| Atorvastatin Calcium | Atorvastatin Calcium | 607 | 176 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 534 | 90 |
| Amlodipine Besylate | Amlodipine Besylate | 480 | 135 |
| Alprazolam | Alprazolam | 441 | 84 |
| Omeprazole | Omeprazole | 417 | 109 |
| Gabapentin | Gabapentin | 399 | 108 |
| Lisinopril | Lisinopril | 398 | 112 |
| Metformin Hcl | Metformin Hcl | 390 | 116 |
| Losartan Potassium | Losartan Potassium | 331 | 86 |
| Azithromycin | Azithromycin | 316 | 177 |
| Fenofibrate | Fenofibrate | 311 | 87 |
| Carvedilol | Carvedilol | 299 | 87 |
| Simvastatin | Simvastatin | 292 | 79 |
| Meloxicam | Meloxicam | 257 | 71 |
| Pantoprazole Sodium | Pantoprazole Sodium | 251 | 71 |
| Glimepiride | Glimepiride | 243 | 71 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 237 | 70 |
| Allopurinol | Allopurinol | 236 | 63 |
| Trazodone Hcl | Trazodone Hcl | 235 | 68 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 229 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 225 | 58 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 222 | 65 |
| Oxycodone Hcl | Oxycodone Hcl | 219 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 209 | 54 |
| Ezetimibe | Ezetimibe | 194 | 62 |
| Tamsulosin Hcl | Tamsulosin Hcl | 194 | 59 |
| Famotidine | Famotidine | 192 | 56 |
| Furosemide | Furosemide | 189 | 58 |
| Zolpidem Tartrate | Zolpidem Tartrate | 180 | 53 |
| Tramadol Hcl | Tramadol Hcl | 172 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 163 | 44 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 161 | 48 |
| Fluticasone Propionate | Fluticasone Propionate | 161 | 66 |
| Ropinirole Hcl | Ropinirole Hcl | 158 | 30 |
| Potassium Chloride | Potassium Chloride | 156 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 146 | 44 |
| Alendronate Sodium | Alendronate Sodium | 142 | 34 |
| Prednisone | Prednisone | 142 | 89 |
| Buspirone Hcl | Buspirone Hcl | 141 | 33 |
| Tizanidine Hcl | Tizanidine Hcl | 140 | 45 |
| Montelukast Sodium | Montelukast Sodium | 137 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 128 | 29 |
| Fluconazole | Fluconazole | 127 | 55 |
| Metformin Hcl Er | Metformin Hcl | 124 | 35 |
| Sertraline Hcl | Sertraline Hcl | 122 | 32 |
| Telmisartan | Telmisartan | 118 | 31 |
| Ozempic | Semaglutide | 117 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 116 | 34 |
| Clonazepam | Clonazepam | 114 | 20 |
| Januvia | Sitagliptin Phosphate | 113 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 109 | 27 |
| Methylprednisolone | Methylprednisolone | 105 | 58 |
| Eliquis | Apixaban | 104 | 33 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 101 | 14 |
| Lorazepam | Lorazepam | 98 | 22 |
| Mounjaro | Tirzepatide | 93 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 89 | 21 |
| Finasteride | Finasteride | 83 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 81 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 78 | 23 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 77 | 25 |
| Linzess | Linaclotide | 76 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 74 | 20 |
| Spironolactone | Spironolactone | 73 | 22 |
| Chlorthalidone | Chlorthalidone | 72 | 20 |
| Diazepam | Diazepam | 70 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 68 | 48 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 67 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 65 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 65 | 21 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 64 | 41 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 62 | 20 |
| Bupropion Xl | Bupropion Hcl | 60 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 60 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 57 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 57 | 15 |
| Solifenacin Succinate | Solifenacin Succinate | 56 | suppressed |
| Xarelto | Rivaroxaban | 56 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 55 | 18 |
| Ibuprofen | Ibuprofen | 55 | 16 |
| Aripiprazole | Aripiprazole | 53 | 14 |
| Trulicity | Dulaglutide | 53 | 12 |
| Carisoprodol | Carisoprodol | 50 | suppressed |
| Topiramate | Topiramate | 49 | suppressed |
| Synthroid | Levothyroxine Sodium | 48 | 14 |
| Colestipol Hcl | Colestipol Hcl | 47 | 14 |
| Warfarin Sodium | Warfarin Sodium | 47 | suppressed |
| Primidone | Primidone | 46 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 45 | 30 |
| Sumatriptan Succinate | Sumatriptan Succinate | 45 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 45 | 11 |
| Fentanyl | Fentanyl | 44 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 42 | 12 |
| Lovastatin | Lovastatin | 41 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 41 | 20 |
| Symbicort | Budesonide/Formoterol Fumarate | 41 | suppressed |
| Estradiol | Estradiol | 40 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 40 | 17 |
| Myrbetriq | Mirabegron | 39 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 38 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 38 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 36 | 24 |
| Mirtazapine | Mirtazapine | 36 | suppressed |
| Novolog Flexpen | Insulin Aspart | 35 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 35 | suppressed |
| Rybelsus | Semaglutide | 35 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 34 | 11 |
| Valacyclovir | Valacyclovir Hcl | 34 | 15 |
| Dilt-Xr | Diltiazem Hcl | 33 | suppressed |
| Lansoprazole | Lansoprazole | 33 | suppressed |
| Ondansetron Odt | Ondansetron | 33 | 14 |
| Testosterone | Testosterone | 33 | suppressed |
| Baclofen | Baclofen | 32 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Atenolol | Atenolol | 31 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 29 | 11 |
| Methocarbamol | Methocarbamol | 29 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 29 | 11 |
| Raloxifene Hcl | Raloxifene Hcl | 29 | suppressed |
| Celecoxib | Celecoxib | 28 | suppressed |
| Amoxicillin | Amoxicillin | 27 | 17 |
| Levetiracetam | Levetiracetam | 27 | suppressed |
| Nystatin | Nystatin | 27 | 15 |
| Amiodarone Hcl | Amiodarone Hcl | 26 | suppressed |
| Oxycontin | Oxycodone Hcl | 26 | suppressed |
| Ramipril | Ramipril | 26 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 26 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 25 | suppressed |
| Cephalexin | Cephalexin | 25 | 12 |
| Irbesartan | Irbesartan | 25 | suppressed |
| Torsemide | Torsemide | 25 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 24 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 16 |
| Jardiance | Empagliflozin | 23 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 23 | suppressed |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 21 | 21 |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 21 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 21 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 20 | 11 |
| Glipizide | Glipizide | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Lactulose | Lactulose | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Vascepa | Icosapent Ethyl | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Carbamazepine Er | Carbamazepine | 17 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Rexulti | Brexpiprazole | 17 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 16 | suppressed |
| Cefdinir | Cefdinir | 15 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Xtampza Er | Oxycodone Myristate | 13 | suppressed |
| Almotriptan Malate | Almotriptan Malate | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 12 | suppressed |
| Hydromorphone Er | Hydromorphone Hcl | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Savella | Milnacipran Hcl | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Armour Thyroid | Thyroid,pork | 11 | suppressed |
| Clozapine | Clozapine | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $122.75 · 7 records | Novo Nordisk Inc | ABRYSVO, COMIRNATY, CREON, LINZESS, MOUNJARO, Ozempic, PREVNAR 20, QULIPTA, Rybelsus, UBRELVY, Wegovy, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error